SCHEMBL6029929

SCHEMBL6029929

CCCCCCCCOC(=O)Nc1sc(CCCCCCCC)c(C)c1C(=O)O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.45
CSNK2A2 P19784 2/20 0.44
CSNK2A1 P68400 2/20 0.44
MAPT P10636 1/20 0.43
TSHR P16473 1/20 0.43
MAPK1 P28482 1/20 0.43
HSD17B10 Q99714 1/20 0.43
CNR1 P21554 1/20 0.43
CNR2 P34972 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
EPHX1 P07099 1/20 0.42
ABCC1 P33527 1/20 0.41
ACHE P22303 6/20 0.41
KMT2A Q03164 1/20 0.40
RAB9A P51151 2/20 0.40
NPC1 O15118 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6031543 1.00 ALDH1A1 (0.45) ALDH1A1CSNK2A2CSNK2A1MAPTTSHR
SCHEMBL6030337 0.85 CNR1 (0.44) ALDH1A1MAPTTSHRMAPK1HSD17B10
SCHEMBL6030952 0.85 CNR1 (0.44) ALDH1A1MAPTTSHRMAPK1HSD17B10
SCHEMBL11480879 0.83 CYP2C9 (0.50) ALDH1A1MAPTTSHRMAPK1CNR1
SCHEMBL6030618 0.77 CSNK2A2 (0.45) ALDH1A1CSNK2A2CSNK2A1TSHRMAPK1
SCHEMBL6029907 0.75 PKM (0.47) ALDH1A1CSNK2A2CSNK2A1MAPTTSHR
SCHEMBL6030373 0.75 CSNK2A2 (0.46) ALDH1A1CSNK2A2CSNK2A1MAPTTSHR
SCHEMBL6031439 0.74 HSD17B10 (0.54) ALDH1A1CSNK2A2CSNK2A1MAPTHSD17B10
SCHEMBL6031306 0.74 HSD17B10 (0.54) ALDH1A1CSNK2A2CSNK2A1MAPTHSD17B10
SCHEMBL6031060 0.74 HSD17B10 (0.54) ALDH1A1CSNK2A2CSNK2A1MAPTHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7064122-B2 Pancreatic lipase inhibitor compounds, their synthesis and use OSI PHARMACEUTICALS, INC. (US) 2006-06-20 US disclosed
EP-1467978-A4 PANCREATIC LIPASE INHIBITOR COMPOUNDS, THEIR SYNTHESIS AND USE OSI PHARM INC (US) 2005-11-02 EP disclosed
EP-1467978-A1 PANCREATIC LIPASE INHIBITOR COMPOUNDS, THEIR SYNTHESIS AND USE OSI Pharmaceuticals, Inc. (US) 2004-10-20 EP disclosed
US-20030195199-A1 Pancreatic lipase inhibitor compounds, their synthesis and use OSI PHARMACEUTICALS, INC. 2003-10-16 US disclosed
WO-2003053944-A1 PANCREATIC LIPASE INHIBITOR COMPOUNDS, THEIR SYNTHESIS AND USE OSI PHARMACEUTICALS, INC. (US) 2003-07-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030195199-A1 Pancreatic lipase inhibitor compounds, their synthesis and use PNLIP, LIPC, CEL ALDH1A1 1832/4885CSNK2A2 1345/4885CSNK2A1 1181/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.